Skip to main content
. 2016 Jul 13;7(34):54714–54722. doi: 10.18632/oncotarget.10591

Figure 5. HDAC6 inhibition prevents LPS-induced VE-cadherin down-regulation in lung tissues.

Figure 5

(A) C57BL/6 mice were divided into four groups: Control (Con, n = 6); LPS (LPS, n = 7), CAY10603 (CAY, n = 6); CAY10603+LPS (CAY+LPS, n = 7). Mice were challenged by CAY10603 for 2 h, then challenged with LPS for 24 h. Lung tissue were collected. (B) C57BL/6 mice were divided into three groups: Control (Con, n = 6); LPS (n = 7); Tubastatin A (TubA)+LPS (n = 6). Mice were challenged by LPS with or without Tubastatin A (TubA) pre-treatment. 24 h after LPS challenge, lung tissues were collected. Representative blots and densitometry analysis of VE-cadherin level in lung tissues. *P < 0.05 versus LPS group.